Sana Biotechnology (NASDAQ:SANA) Trading Down 6.2% – Time to Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price fell 6.2% on Thursday . The stock traded as low as $3.84 and last traded at $3.8450. 306,599 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 3,117,871 shares. The stock had previously closed at $4.10.

Analysts Set New Price Targets

Several brokerages recently issued reports on SANA. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Bank of America dropped their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Sana Biotechnology presently has an average rating of “Moderate Buy” and a consensus price target of $9.33.

Sana Biotechnology Stock Performance

The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -5.06 and a beta of 2.16. The business has a 50 day simple moving average of $3.43 and a 200-day simple moving average of $3.42.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. As a group, research analysts anticipate that Sana Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors have recently bought and sold shares of the stock. Alphabet Inc. purchased a new position in Sana Biotechnology during the 2nd quarter worth $9,816,000. Dimensional Fund Advisors LP grew its stake in shares of Sana Biotechnology by 118.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 291,268 shares of the company’s stock worth $839,000 after acquiring an additional 158,190 shares in the last quarter. LaSalle St. Investment Advisors LLC purchased a new stake in shares of Sana Biotechnology in the second quarter valued at about $77,000. SCS Capital Management LLC purchased a new stake in shares of Sana Biotechnology in the second quarter valued at about $284,000. Finally, Rockefeller Capital Management L.P. lifted its position in shares of Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after purchasing an additional 4,088 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.